Medical devices, healthcare technology and the business of care
510(k) clearance · K253158

VyBrate VBR System

Vy Spine, LLC · Decision date Jan 7, 2026

FDA DECISIONK253158

What did the FDA decide?

FDA records K253158 as a 510(k) premarket notification, with a decision dated Jan 7, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Jan 7, 2026

FDA source record

Regulatory record facts

Identifier
K253158
Regulatory pathway
510(k) premarket notification
Applicant
Vy Spine, LLC
Product code
MQP
Decision code
SESE
Decision date
Jan 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Spinal Vertebral Body Replacement Device.

Applicant
Vy Spine, LLC
Product code
MQP
FDA device class
2

FDA decision timeline

  1. K253158 received

    Application receipt date recorded by FDA.

  2. K253158 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code MQP

Product / regulatory recordCompanyPathwayDecision dateSource
SeaSpine Orthopedics Corporation510(k) clearanceOct 29, 2026FDA
Foundation Surgical Group510(k) clearanceJul 31, 2026FDA
Signus Medinzintechnik GmbH510(k) clearanceJul 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vy Spine, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Bountiful, UT

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records